Is your portfolio ready for MFN policy?

Most Favoured Nation (MFN) pricing policy is a pharmaceutical pricing mechanism that links the price the US pays for a drug to the lowest price paid by a comparable set of countries — typically OECD nations or major European markets. Under an MFN rule, if another country negotiates a lower price for the same drug, the US price must be adjusted downward to match it.

MFN policy represents a fundamental shift from the traditional US pricing model. Rather than setting US prices in isolation, manufacturers would need to account for their entire global pricing architecture when setting — or maintaining — any price in a reference country basket.

International Reference Pricing (IRP) is a broad system where one country uses prices in other countries as benchmarks when setting its own reimbursed price. MFN policy is a specific, more aggressive application of this concept: rather than using foreign prices as a guide, the MFN mechanism directly caps the US price at the lowest international comparator.

The key distinction is directionality and binding effect. Under conventional IRP, a country like Germany or France may reference UK or Spanish prices when negotiating, often resulting in a price corridor. Under MFN, the US price is contractually required to match the lowest comparable global price — creating a hard floor that propagates across every market that references the US in its own IRP system.

For pharmaceutical companies, MFN therefore creates a compounding risk: a price reduction in one market can cascade through multiple IRP baskets simultaneously.

MFN policy fundamentally changes how pharmaceutical companies must approach global launch sequencing, pricing decisions, and portfolio management. The strategic implications include:

• Launch sequencing: Launching in lower-priced markets early in a product's lifecycle creates reference prices that can lock in lower US pricing under MFN, potentially eliminating billions in US revenue.
• Price differentiation: The current model of significant price gaps between the US and ex-US markets becomes untenable, forcing companies to rethink global pricing architecture.
• IRP cascade risk: Because many countries reference the US in their own IRP frameworks, a US price reduction can trigger further reductions globally — a "race to the bottom" effect.
• Portfolio prioritisation: Companies with broad portfolios face disproportionate exposure, requiring product-by-product MFN risk modelling.
• Contracting complexity: Existing rebate and contracting structures with US payers may need to be restructured to accommodate MFN compliance.

MFN readiness refers to an organisation's preparedness — across data, technology, processes, and governance — to model, manage, and respond to the pricing implications of Most Favoured Nation policy.

A company with high MFN readiness can: accurately model which products are exposed and by how much; run scenario analyses across launch sequences and price points; integrate IRP data from 100+ markets in real time; align cross-functional teams around a coherent response strategy; and act quickly if policy is enacted.

Readiness matters because building these capabilities takes time — typically 12 to 18 months — and companies that begin preparation late risk being forced into reactive decisions with limited options. Organisations that achieve MFN readiness before policy enactment retain strategic control of their pricing outcomes.

Comprehensive MFN preparation requires data across several dimensions:

• IRP intelligence: Real-time and historical pricing data across 100+ reference markets, including basket compositions, update frequencies, and adjustment triggers.
• Global Launch Sequence (GLS) data: Detailed records of every product's historical launch sequence, launch prices, and subsequent price changes across all markets.
• US payer intelligence: Comprehensive Health Plan (CHP) data, current contracting structures, and net price calculations that feed into MFN compliance models.
• Portfolio mapping: Cross-market product equivalence data to identify which products fall under MFN scope and how IRP linkages apply.
• Scenario modelling: The capability to model price impact across multiple "what if" scenarios — different policy timelines, reference basket compositions, and response strategies.

Most companies find that assembling and structuring this data from disparate internal and external sources is the single most time-consuming element of MFN readiness.

Building comprehensive MFN readiness typically requires a minimum of 12 to 18 months. The key workstreams and estimated timelines are:

• Data foundation setup: 3 to 6 months — sourcing, cleaning, and structuring IRP, GLS, and payer data.
• Platform integration: 4 to 8 months — deploying or integrating pricing intelligence platforms capable of running MFN modelling.
• Team training and process design: 3 to 6 months — upskilling commercial, market access, and finance teams; establishing governance frameworks.
• Portfolio analysis and strategic planning: 2 to 4 months — running product-level exposure assessments and developing mitigation strategies.

These workstreams are typically partially parallel, but the data foundation must be largely in place before meaningful modelling or planning can begin. Companies starting from scratch in Q1 2026 face a tight window given estimates of a 2026–2027 policy enactment range.

GPI's MFN Readiness Assessment evaluates pharmaceutical organisations across five critical dimensions:

• Data infrastructure: The availability, quality, and comprehensiveness of IRP and global pricing data across your portfolio and reference markets.
• Platform capability: Whether your technology stack can model MFN scenarios, run cross-market analyses, and generate strategic outputs at portfolio scale.
• Process maturity: How well-defined and operationalised your cross-functional processes are for pricing decisions, scenario response, and policy monitoring.
• Governance and alignment: Whether leadership teams, market access, finance, and commercial functions share a coherent, aligned view of MFN risk and response strategy.
• Strategic readiness: The degree to which MFN implications are already embedded into pipeline planning, launch sequencing decisions, and long-term pricing strategy.

Global Pricing Innovations (GPI) is a specialist pharmaceutical pricing intelligence consultancy that helps major pharmaceutical companies prepare for and navigate MFN policy. GPI's support spans three core pillars:

• Curated data: Proprietary IRP intelligence across 100+ markets, Global Launch Sequence data, and US payer intelligence (CHP data) — the data foundation required for MFN readiness.
• Technology platforms: GPI Pulse and GPI Horizon deliver real-time pricing intelligence and scenario modelling capabilities, enabling portfolio-wide MFN impact analysis.
• Specialist expertise: GPI's team of pharmaceutical pricing experts provides strategic advisory support, from exposure assessment through to governance design and launch strategy refinement.

GPI works with major pharmaceutical companies including clients across the top 20 global biopharma organisations. To discuss your organisation's MFN readiness, complete the assessment above or contact the GPI team directly at globalpricing.com/contact-us.